Innoveren Scientific Inc (OTC : IVRN) Stock

Innoveren Scientific Inc., formerly H-CYTE, Inc., is focused on acquiring and developing early-stage companies or their technologies in the areas of therapeutics, medical devices, and diagnostics. The Company operates in two divisions: Autologous Infusion Therapy (Infusion Division), and Biotech Development (Biotech Division). Its Infusion Division develops and implements treatment options in autologous cellular therapy (PRP-PBMC) to treat chronic lung disorders. The Infusion Division¿s customer base consists of individuals who are suffering from chronic lung disease that are searching for alternative or adjunct forms of treatment. Its Biotech Division develops and distributes a biology combining its PRP-PBMC (PRP) technology with Rion¿s exosomes technology for the treatment of chronic obstructive pulmonary disease (COPD). It has membership interests in Jantibody LLC, which is focused on developing immunotherapies targeted towards ovarian cancer, pancreatic cancer, and mesothelioma.